George Washington Hatchet, January 2023
The George Washington School of Medicine and Health Sciences achieved a 97 percent success rate after conducting the first-ever human trials of the mRNA HIV vaccine over the past year, according to a release the school issued last month.
Researchers created a molecule inside the vaccine that elicits a response from bnAb precursor B cells, which eventually turn into cells that produce bnAbs – neutralizing antibodies that target the HIV virus, according to the study’s release. David Diemert, the clinical director of the GW Vaccine Research Unit, said in the release that the trials produced an efficacy rate that is more than 66 percent higher than any other HIV vaccine that has been tested on humans.
